Detail akcie Almirall online

Business Summary: Almirall SA is a Spain-based company principally engaged in the pharmaceuticals manufacture. The Company focuses on development and marketing of drugs applied in various therapeutic areas, such as nervous system, gastrointestinal, dermatological, respiratory system, antiinfectives, as well as antineoplastic and immunomodulating agents. The Company's activities are divided into four business segments: Own network, which focuses on the commercialization of pharmaceuticals through own brand names; Licenses, which sells product rights to third parties; Research and development (R&D), which is responsible for the creation of drug candidates, as well as Dermatology, which includes sale of dermatological medicines in the United States. The Company operates through numerous subsidiaries in Europe, the Americas, Africa, Asia and Australia.
Financial Summary: BRIEF: For the three months ended 31 March 2022, Almirall SA revenues decreased 1% to EUR218.8M. Net income decreased 32% to EUR20.4M. Revenues reflect United States segment decrease of 33% to EUR15.7M. Net income also reflects Research and Development Expenses increase of 57% to EUR21.1M (expense), Exchange rate differences decrease of 95% to EUR300K (income). Basic Earnings per Share excluding Extraordinary Items decreased from EUR0.17 to EUR0.11.